Lamivudine and Adefovir Motif Variants Detected in chronic Hepatitis B patients

Basit Öğe Kaydı
dc.contributor.authorÖzekinci T.
dc.contributor.authorMese S.
dc.contributor.authorOzbek E.
dc.contributor.authorAtmaca S.
dc.date.accessioned2024-04-24T17:58:32Z
dc.date.available2024-04-24T17:58:32Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aims: Chronic hepatitis B is an important health problem worldwide. Lamivudine, adefovir, entecavir and telbivudine are the oral drugs licensed for the treatment of patients with chronic hepatitis B. Implementation of antiviral therapy leads to the emergence of mutant strains during the treatment in chronic hepatitis B. Primary antiviral resistance may be rarely encountered. The aims of this study were to detect the resistance patterns of Hepatit B Virus strains in treatment-naive chronic hepatitis B patients Materials and Methods: A total of 147 CHB patients were included to this study which was carried on between January 2007-December 2010. HBV DNA levels were detected by using the Real time PCR (COBAS Ampli-Prep/COBAS TaqMan HBV Test). HBV-DNA was extracted from the sera of the patients by using extraction kit (Invisorb, Instant Spin DNA/RNA Virus Mini Kit, Germany). A line prob assay (Inno-Lipa HBV DR v2, Innogenetics N.V, Ghent, Belgium) was used to determine motif variants at viral polymerase gene fragment in HBVDNA samples of these patients and evaluated colorimetrically. Results. In 147 patients antiviral resistance rate was found 17% (25/147) for lamivudin, 5.44% (8/147) adefovir, 0.68%(1/147) lamivudin and adefovir. Various mutations were detected. This mutations; responsible for lamivudine resistance YMDD+YVDD (n=10), YMDD+YIDD (n=12), YIDD (n=2), YVDD (=1); responsible for adefovir resistance N236T (n=3), A181T (n=5); responsible for lamivudine and adefovir resistance YMDD+YIDD+N236T (n=1). Conclusions: As a conclusion, it is thought that drug resistance should be followed up regularly, the determination of HBV drug resistance as immediate as possible period may be instructive for the treatment and follow-up in CHB patients. Although determination of known mutations with Inno Lipa DR v2 method is disadvantage, because of ease of application and the determination of both lamivudinadefovir resistance in a short time, it can be used for the treatment and follow-up in CHB patients. © Societá Editrice Universo (SEU).en_US
dc.identifier.doi10.7471/CT.2014.1654
dc.identifier.endpage17en_US
dc.identifier.issn0009-9074
dc.identifier.issue1en_US
dc.identifier.pmid24589944
dc.identifier.scopus2-s2.0-84895111144
dc.identifier.scopusqualityQ2
dc.identifier.startpage13en_US
dc.identifier.urihttps://doi.org/10.7471/CT.2014.1654
dc.identifier.urihttps://hdl.handle.net/11468/23975
dc.identifier.volume165en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.relation.ispartofClinica Terapeutica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiviral Resistanceen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectInno-Lipa Hbv Dr V2en_US
dc.titleLamivudine and Adefovir Motif Variants Detected in chronic Hepatitis B patientsen_US
dc.titleLamivudine and Adefovir Motif Variants Detected in chronic Hepatitis B patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu